[CAS NO. 855291-54-2] ABT-107
PRODUCTS SPECIFICATIONS [855291-54-2]
DESCRIPTION [855291-54-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 320.39 |
| Molecular Formula | C19H20N4O |
| SMILES | [C@H]1(C2CCN(CC2)C1)OC3=CC=C(C4=CC=C(NC=C5)C5=C4)N=N3 |
Summary
In Vivo
ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally,100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly,
100%), and good CNS penetration in rodents with a brain/plasma ratio of 1
[1]
.
ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB
[1]
.
ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S
9
-GSK3 and decreases p-tau in mouse cortex and hippocampus in mice
[1]
.
ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Rats (male Sprague-Dawley; 350-380 g b.wt.) [1] . |
| Dosage: | 1, 3 μmol/kg. |
| Administration: | I.P. daily for 3 consecutive days. |
| Result: |
Induced a significant, dose-dependent increase in ACh release by day 3 of repeated administration.
Higher doses may be required to evoke ACh release in naive rats not engaged in stimulated, i.e., cognitive-related behavior. |
| Animal Model: | Female TAPP (and wild-type littermates) mice [1] . |
| Dosage: | 1 mg/kg. |
| Administration: | Continuous subcutaneous infusion for 2 weeks. |
| Result: | Produced a dose-dependent increase in Ser9 phosphorylation in the cingulate cortex 15 min after acute administration in mice. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 312.12 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.1212 mL | 15.6060 mL | 31.2120 mL |
| 5 mM | 0.6242 mL | 3.1212 mL | 6.2424 mL |
| 10 mM | 0.3121 mL | 1.5606 mL | 3.1212 mL |
References
- [1] R Scott Bitner, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86.
- [2] Tanuja Bordia, et al. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277-84.